The Company
The Company
Promore Pharma in Brief
Vision and Strategy
Market
Team
Board of Directors
Projects
Projects
Ropocamptide – Healing of Chronic Wounds
Publications
Investors
Investors
Promore Pharma on Nasdaq First North Growth Market
Certified Adviser
The Share
Shareholders
Warrant Programs
Share capital development
Analysts
Financial Reports
Press Releases
Prospectuses
Presentations and Events
Calendar
Subscribe
Corporate Governance
Corporate Governance
Corporate Governance
General Meeting
General Meetings
Nomination Committee
Nomination Committees
The Board of Directors
Board of Directors
The Management
Management
Remunerations and Remuneration Committee
Auditor and Audit Committee
Articles of Association
Certificate of Registration
Media
Media
Press Releases
Imagebank
Promore Pharma in Media
Subscribe
Contact
Contact
Office
Investors
Media
Svenska
The Company
Promore Pharma in Brief
Vision and Strategy
Market
Team
Board of Directors
Projects
Ropocamptide – Healing of Chronic Wounds
Publications
Investors
Promore Pharma on Nasdaq First North Growth Market
Certified Adviser
The Share
Shareholders
Warrant Programs
Share capital development
Analysts
Financial Reports
Press Releases
Prospectuses
Presentations and Events
Calendar
Subscribe
Corporate Governance
Corporate Governance
General Meeting
General Meetings
Nomination Committee
Nomination Committees
The Board of Directors
Board of Directors
The Management
Management
Remunerations and Remuneration Committee
Auditor and Audit Committee
Articles of Association
Certificate of Registration
Media
Press Releases
Imagebank
Promore Pharma in Media
Subscribe
Contact
Office
Investors
Media
Media
Press Releases
Imagebank
Promore Pharma in Media
Subscribe
Contact
Erik Magnusson
Chief Financial Officer (CFO)
+46 70 856 52 45
Press Releases
Non-regulatory press releases
Regulatory press releases
All press releases
All years
2023
2022
2021
2020
2019
2018
2017
2016
2015
2013
April 20, 2023
Invitation to a presentation of the results from Promore Pharma’s clinical trial PHSU05
February 27, 2023
Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Fourth Quarter 2022
February 27, 2023
Promore Pharma reaches the Clean File milestone in its phase II clinical trial with ensereptide
November 24, 2022
Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Third Quarter 2022
August 23, 2022
Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Second Quarter 2022
August 10, 2022
Promore Pharma granted EU patent regarding treatment of chronic wounds
May 13, 2022
Invitation to Conference Call regarding Promore Pharma’s Interim Report for the First Quarter 2022
February 9, 2022
Invitation to Conference Call regarding Promore Pharma’s Year-end Report 2021
December 8, 2021
Promore Pharma granted US patent regarding treatment of chronic wounds
November 19, 2021
Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Third Quarter 2021
August 17, 2021
Invitation to Conference Call regarding Promore Pharma’s Q2 Report 2021
May 26, 2021
Promore Pharma participates in “Småbolagsdagarna 2021”, an event organized by Aktiespararna
May 17, 2021
Invitation to Conference Call regarding Promore Pharma’s Q1 Report 2021
May 12, 2021
Promore Pharma is granted a US patent regarding skin scarring
March 31, 2021
Promore Pharma comments on media reports about ensereptide
February 16, 2021
Invitation to Presentation of Promore Pharma’s Year-end report for 2020
November 20, 2020
Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Third Quarter 2020
October 27, 2020
Nomination Committee Appointed for the Annual General Meeting 2021 in Promore Pharma
August 19, 2020
Invitation to Presentation of Promore Pharma’s Interim Report for the Second Quarter 2020
July 14, 2020
Promore Pharma is Granted a Patent for ropocamptide in the US
May 25, 2020
Invitation to Conference Call regarding Promore Pharma’s Interim Report for the First Quarter 2020
February 13, 2020
Invitation to Presentation of Promore Pharma’s Year-end report for 2019
November 12, 2019
Promore Pharma is granted a patent for PXL01 in the US
October 17, 2019
Nomination Committee Appointed for the Annual General Meeting 2020 in Promore Pharma
October 6, 2019
Promore Pharma Rights issue – correction of date
August 27, 2019
Promore Pharma is granted a patent for LL-37 in Japan
August 23, 2019
Invitation to Presentation of Promore Pharma’s Interim report for the second quarter 2019
May 15, 2019
Invitation to Presentation of Promore Pharma’s Interim report for the first quarter 2019
February 20, 2019
Invitation to Presentation of Promore Pharma’s Year-end report for 2018
January 31, 2019
Subscription price for Promore Pharma’s warrants TO1 determined
December 17, 2018
PharmaResearch Products Ltd use call option in Promore Pharma
November 9, 2018
Nomination Committee Appointed for the Annual General Meeting 2019 in Promore Pharma
September 6, 2018
Promore Pharma has conducted Investigator Meeting for HEAL LL-37 in Poland
September 3, 2018
Promore Pharma Plans to Expand Indications of Therapeutic Peptide PXL01 in the Field of Dermal Scarring
August 14, 2018
Invitation to Presentation of Promore Pharma’s Interim report for the second quarter 2018
May 9, 2018
Invitation to Presentation of Promore Pharma’s Interim report for the first quarter 2018
April 19, 2018
Västra Hamnen Corporate Finance Initiates Coverage on Promore Pharma
April 4, 2018
Two new smart-phone based imaging products have been adopted by Promore Pharma AB
February 1, 2018
Promore Pharma is granted a patent for PXL01 in the US
October 31, 2017
Promore Pharma Signs Agreement with CRO PCG Clinical Services
October 30, 2017
Promore Pharma Completes Extensive European Collaboration Regarding DPK-060
September 21, 2017
Promore Pharma Signs Manufacturing Agreement with APL
September 12, 2017
Promore Pharma presents at the symposium for hard-to-heal wounds in connection with Nordic Life Science Days
May 19, 2017
Interim report January – March 2017
May 17, 2017
Promore Pharma AB files phase III clinical trial application in India
April 26, 2017
Promore Pharma AB elects Marianne Dicander Alexandersson as New Board Member and outlines plans for IPO
December 21, 2016
Promore Pharma and Cellastra Inc. Announce Phase III Clinical Collaboration to Develop Therapeutic Peptide PXL01 for the US Market
December 15, 2016
Promore Pharma is Seeking an Office Manager in Stockholm
August 22, 2016
New Chief Financial Officer in Promore Pharma
July 8, 2016
Promore Pharma Announces a Strategic Collaboration with Technomark Life Sciences
July 5, 2016
Pergamum AB and Lipopeptide AB Change Name to Promore Pharma
May 31, 2016
Promore Pharma Obtains Positive Feedback in Dialogue with The Medical Products Agency of Sweden
March 8, 2016
Lipopeptide AB Announces a Strategic Collaboration with Pharmaresearch Products LTD
May 28, 2015
Pergamum AB Announces Ownership Restructuring
October 10, 2013
Pergamum Announces Final Data from Phase I/II Study in Patients with Chronic Leg Ulcers
June 27, 2013
Pergamum Reports Positive Follow-Up Data from a Phase II Clinical Trial of PXL01 for Prevention of Post-Surgical Adhesions
February 8, 2013
Pergamum Announces a Strategic Collaboration with Cadila Pharmaceuticals Ltd.
